Gefitinib has yielded clinically positive responses in patients with advanced and metastatic non-small-cell lung cancer (NSCLC) [3] with hyperactive and mutated EGFR genes, primarily in exon 19 (del 19) or exon 21 (L858R) regions [4]. Here, EGFR is linked to non-small cell lung carcinoma.